BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//CERN//INDICO//EN
BEGIN:VEVENT
SUMMARY:Luisa Ronga - The Role of Selenoenzymes in the Toxic and Therapeut
 ic Activity of Metallic Compounds
DTSTART:20260522T090000Z
DTEND:20260522T110000Z
DTSTAMP:20260513T004800Z
UID:indico-event-39035@indico.in2p3.fr
DESCRIPTION:Mammalian selenoproteins containing selenocysteine (Sec)\, the
  sulfur-to-selenium substituted variant of cysteine (Cys)\, at their activ
 e site\, play critical roles in redox homeostasis\, antioxidant defense\, 
 and cellular signaling. Due to the high nucleophilicity and reactivity of 
 selenocysteine\, these proteins represent potential target of toxic trace 
 metal (Hg) and metallodugs (Au\, Pt)1.  \nThis presentation will elucidat
 e the key role of Thioredoxin Reductases (TrxR) and Glutathione Peroxidase
 s (Gpx)\, two main families of selenoenzymes\, both in the toxicity of MeH
 g+\, a potent neurotoxicant\, and in the therapeutic activity of gold-base
 d drugs. \nThe reactivity of TrxR and Gpx with MeHg+ or gold(III) cyclome
 tallated compounds was evaluated by an integrated experimental\, theoretic
 al and cellular approach.\nOur data offer a clear molecular explanation fo
 r the inhibition of the selenoenzymes TrxR1 and GPx1 by MeHg+\, as well as
  for the associated toxic effects. This process involves MeHg+ preferentia
 lly reacting with SeCys\, which is followed by the involvement of neighbor
 ing Cys residues2. We also provide mechanistic details and evidence suppor
 ting the use of selenopeptides for MeHg+ detoxification strategies3.\nMore
 over\, the intrinsic preferences of cyclometallated gold(III) compounds fo
 r Sec- over Cys-arylation was demostrated in peptide models4 and translate
 d to functional inhibition of selenoenzymes5. This activity can mediate th
 e cytotoxicity of these metallodrugs\, highlighting their potential in ant
 icancer therapy.\nReferences\n1. Bernabeau de Maria M.\, Lamarche J.\, Ron
 ga L. \, Messori L.\, Szpunar J.\,  Lobinski R. Coordination Chemistry Re
 views (2023)\, 474\, 214836.\n2. Bernabeau de Maria M.\, Zangmo T.\, A. Ga
 wor\, E. Bulska\, L. Messori\, J. Szpunar\, R. Lobinski\, K. Miqueu\, Rong
 a L. Inorganic Chemistry Frontiers (2026)\,  13\, 32.\n3. Bernabeu De Mar
 ia M.\, Tesauro D.\, Prencipe F.\, Saviano M.\, Messori L.\, Enjalbal C.\,
  Lobinski R.\, Ronga L.\, Inorganic Chemistry (2023)\, 62\, 14980.\n4. Nak
 ahata D.H.\, Kanavos I.\, Zubiria-Ulacia M.\, Inague A.\, Salassa L.\, Lob
 inski R.\, Miyamoto S.\, Mattin Matxain J.\, Ronga L.\, de Paiva R.E.F\, C
 hemistry a European J. (2024)\, 30\, e202304050.\n5. Kanavos I.\, Nakahata
  D.\, Barrett M.\, Dos Santos A.F.\, Zubiria-Ulacia M.\, Pieslinger G.E.\,
  Da Silva Teixeira A.B.\, Ribeiro Reily Rocha C.\, Eberle J.\, Lobinski R.
 \, Mattin Matxain J.\, Hall M.D.\, Friedmann Angeli J.P.\, Arnér E.S.J.\,
  Ronga L.\, R. De Paiva\, Free Radical Biololgy and Medicine (2026)\, 247\
 , 139.\n \n\nhttps://indico.in2p3.fr/event/39035/
LOCATION:LP2i
URL:https://indico.in2p3.fr/event/39035/
END:VEVENT
END:VCALENDAR